多烯磷脂酰胆碱联合水飞蓟宾治疗非酒精性脂肪肝疗效观察

doi:10.3969/j.issn.1672-5069.2014.01.024

Abstract

Liao Wenqiu, Liu Xiaoye，Zhang Li.. Polyene phosphatidyl choline and silibinin in treatment of patients with nonalcoholic fatty liver[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 196-197.

[1] Fan JG，Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol，2009，50:204-210.
[2] Angulo P. GI epidemiology:nonalcoholic fatty liver disease.Aliment Pharmacol Ther，2007（8）:883-889.
[3] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志，2007，10（1）：1-3.
[4] Cheung O，Sanyal A J． Abnormalities of lipid metabolism in nonalcoholic fatty liver disease．Semin Liver Dis，2008，28（4）:351-359．
[5] Kohjima M，Enjoji M，Higuchi N， et al． Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med，2007，20（3）:351-358．
[6] 曾民德．脂肪肝发病机制及其“二次打击”的假设．中华消化杂志，2002，22（3）:167-168．
[7] 陈潇迪,熊全,张霹云, 等. 多烯磷脂酰胆碱对大鼠非酒精性脂肪性肝病的防治作用观察．实用肝脏病杂志,2012,15（6）:548-550.
[8] Torres DM，Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology，2008，134（6）:1682-1698.
[9] Detaille D, Sanchez C, Sanz N, et al. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perfused rat hepatocytes. Life Sci,2008,82:1070-1076.
[10] Ka SO, Kim KA, Kwon KB, et al. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insight pathway. Int J Med,2009,23:633-637.
[11] 阮建文, 杨京. 水飞蓟宾胶囊治疗代谢综合征相关脂肪性肝病30例. 世界华人消化杂志,2010,18:3151-3154.
[12] 程慧桢, 王海燕, 崔凤芹, 等. 水飞蓟宾胶囊治疗单纯性脂肪肝的临床疗效观察. 实用肝脏病杂志,2009,12:457-459.

[1]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[2]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[3]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[4]	Xie Zhanfeng, Jia Jizhen, Zhao Shufang. Combination of notoginseng total saponin and silybin in treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 623-624.
[5]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.
[6]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.
[7]	Liang Shouzan, Huang Huiyi. Efficacy of entecavir and silibinin combination in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 208-211.
[8]	Wang Qian,Guo Ping. Application of fibroscan and anthropometric parameters in diagnosis of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 754-755.
[9]	Li Yan，Wang Caihua.. Hot spots in dietary therapy in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 529-531.
[10]	Pang Xiaoning，Liu Yanjun.. A comparative study of liraglutide,sitagliptin and pioglitazone in the treatment of patients with nonalcoholic fatty liver diseases and type 2 diabetes mellitus [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 604-605.
[11]	Xu Jian.. Combination of entecavir and polyene phosphatidyl choline therapy in treatment of patients with hepatitis B liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 620-622.
[12]	Guan Jun, Xu Ye. Risk factors of nonalcoholic fatty liver diseases in adolescents [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 347-349.
[13]	Sun Changgui， Zeng Jing，Sun Wanlu，et al.. Changes of estimated glomerular filtration rates in healthy check-up adults with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 165-170.
[14]	Cui Xiaomeng, Liu Xin, Shi Haitao, et al.. Effects of diammonium glycyrrhizinate lipid ligand on AMPKα signaling pathways in rats with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 55-59.
[15]	Zeng Mingde. Achievements and perspectives in nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 129-131.

Polyene phosphatidyl choline and silibinin in treatment of patients with nonalcoholic fatty liver

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments